Top Story

Readmission rate after C. difficile discharge nearly double other discharges

March 27, 2015

The proportion of 30-day readmissions among patients discharged after Clostridium difficile infections was nearly twice that of other patients discharged, researchers from Detroit Medical Center reported.

The researchers noted that reductions in C. difficile infections will be crucial under the Hospital-Acquired Condition Reduction Program that CMS is initiating, which will penalize hospital funding for high-rates of hospital-acquired infections.

In the Journals

Anti-HCV seropositivity not associated with metabolic syndrome

March 27, 2015
Anti-hepatitis C virus infection seropositivity was not associated with metabolic syndrome among Taiwanese adults, regardless of age, gender and fibrosis, according to…
Breaking News

Senate adjourns without voting on bill to repeal sustainable growth rate

March 27, 2015
The U.S. Senate left for its 2-week spring break without voting on a bill that repeals the sustainable growth rate, leaving physicians to face a 21% payment cut if…

AeroVanc reduces MRSA in patients with cystic fibrosis

March 27, 2015
The first inhaled antibiotic in development to address the mounting issue of MRSA lung infection in patients with cystic fibrosis met the primary endpoint in a phase 2…

Japan approves Sovaldi for HCV genotype 2

March 27, 2015
The Japanese Ministry of Health, Labour and Welfare has approved Sovaldi to suppress viremia in patients with chronic hepatitis C virus genotype 2 infection, with or…
More News Headlines »
CME
j526

Regimen Selection in HIV: Considering New Options to Optimize Outcomes

This activity is supported by an educational grant from Gilead Sciences Medical Affairs.

More than two decades into the antiretroviral therapy (ART) era, there are numerous options for HIV treatment. The goal…
More »
Meeting News Coverage Video
thumbnail for video 4129869191001

Video: NIAID Ebola vaccine well tolerated, immunogenic

March 23, 2015
WILMINGTON, Del. — Julie Ledgerwood, DO, of the National Institute of Allergy and Infectious Diseases' Vaccine…
More »
CME CNE CPE Video
Advances in Pharmacokinetic Enhancers in HIV Treatment: What You Need to Know to Optimize Outcomes

Advances in Pharmacokinetic Enhancers in HIV Treatment: What You Need to Know to Optimize Outcomes

This activity is supported by an educational grant from Bristol-Myers Squibb.

Protease inhibitors (PIs) have played an instrumental role in decreasing mortality andmorbidity among HIV-infected…
More »
morganatic-roan